Dan Dearen

Mr. Dearen was appointed to the Board of Directors in September 2025. He brings nearly 40 years of leadership experience in the medical device and life sciences sectors, with a proven track record of guiding companies through critical financial milestones and creating shareholder value through disciplined execution.

Mr. Dearen previously served as President, co-founder, and Chief Financial Officer of Axonics, Inc., where he led the company through its IPO and rapid commercial growth, helping more than 300,000 patients worldwide. Axonics was acquired by Boston Scientific in 2024 for $3.7 billion. Prior to Axonics, he was Chief Operating and Financial Officer of Vessix Vascular, Inc., where he played a key leadership role until its acquisition by Boston Scientific in 2012 for $425 million.

Mr. Dearen has also served on the boards of several innovative medical technology companies. Until July 2024, he chaired the Audit Committee and served as a Board member at Endotronix, a company advancing heart failure care through pulmonary artery pressure and vital sign monitoring. He currently serves as Audit Committee Chair and Board member at JenaValve Technology, a leader in transcatheter heart valve solutions, and BetaBionics (Nasdaq: BBNX), developer of the iLet Bionic Pancreas, an autonomous insulin delivery system for patients with diabetes.

Throughout his career, Mr. Dearen has been instrumental in advancing transformative medical technologies, driving operational and financial execution, and building long-term value for both private and publicly traded companies.